{"result": {"id": "chatcmpl-618", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "{\n    \"title\": \"Cornea Research & Treatment Network\",\n    \"summary\": \"This report analyzes a network focused on corneal research and treatment, highlighting key entities, their relationships, and significant findings. The network comprises researchers, clinicians, and patients working to understand and treat corneal diseases.  It utilizes cutting-edge technologies like CRISPR/Cas9 for gene editing and advanced imaging techniques to diagnose and manage conditions such as neovascularization. The network's impact is substantial, contributing to the development of new treatments and improving patient outcomes.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The network's focus on cutting-edge research and treatment for corneal diseases, coupled with its significant impact on patient care, suggests a high level of influence and potential for further advancement in the field.\",\n    \"findings\": [\n        {\n            \"summary\": \"Significant advancements in gene editing techniques like CRISPR/Cas9 are being explored to treat corneal neovascularization.\",\n            \"explanation\": \"CRISPR/Cas9 technology holds immense promise for treating corneal neovascularization. Researchers can precisely target and modify the VEGFA gene, which plays a crucial role in angiogenesis (blood vessel formation). This targeted approach offers potential for more effective and less invasive treatment options compared to traditional methods. The network's focus on this cutting-edge technology signifies its commitment to developing innovative solutions for corneal diseases.\"\n        },\n        {\n            \"summary\": \"The study of al neovascularization is a key focus in the network's research efforts.\",\n            \"explanation\": \"Al neovascularization, or abnormal blood vessel growth, is a significant challenge in treating corneal diseases. The network's dedicated research on this area aims to develop targeted therapies and improve patient outcomes. This focus highlights the network's commitment to addressing specific challenges within corneal disease management.\"\n        },\n        {\n            \"summary\": \"The network utilizes advanced imaging techniques like OCT (Optical Coherence Tomography) for accurate diagnosis and monitoring of corneal diseases.\",\n            \"explanation\": \"OCT is a non-invasive imaging technique that provides detailed images of the cornea. This technology allows for precise measurements of corneal thickness, vascularization, and other structural abnormalities. The network's use of OCT underscores its commitment to utilizing advanced technologies to improve diagnostic accuracy and patient care.\"\n        },\n        {\n            \"summary\": \"The network collaborates with leading institutions and researchers worldwide to advance knowledge and develop new treatments.\",\n            \"explanation\": \"Collaboration is crucial for accelerating progress in corneal research. The network's participation in international collaborations allows for the exchange of expertise, resources, and data, ultimately contributing to a broader understanding of corneal diseases and their treatment.\"\n        },\n        {\n            \"summary\": \"The network plays a vital role in educating patients about corneal health and disease management.\",\n            \"explanation\": \"Patient education is essential for empowering individuals with knowledge about their condition. The network's efforts to educate patients on proper care, prevention strategies, and available treatment options contribute to improved patient outcomes and overall well-being.\"\n        }\n    ]\n} \n\n\n\n", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1743304724, "model": "gemma2:2b", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_ollama", "usage": {"completion_tokens": 649, "prompt_tokens": 2048, "total_tokens": 2697, "completion_tokens_details": null, "prompt_tokens_details": null}}, "input": {"messages": [{"content": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n5421,PDT,\"PDT, or photodynamic therapy, is a treatment used in studies to address corneal neovascularization. This procedure involves using light to activate a photosensitizing agent, which then targets and destroys the abnormal blood vessels in the cornea. \n\",6\n105,BEVACIZUMAB,\"**Bevacizumab** is a protein drug used in subconjunctival injection for corneal neovascularization. It is also used to suppress vascularization and treat conditions like corneal transplantation, specifically in the context of  Corneal Neovascularization (CNV). Bevacizumab has been studied as a treatment option for various diseases, including those related to CNV. \n\",11\n694,CORNEAL NEOVASCULARIZATION,\"**Corneal neovascularization** is a medical condition characterized by abnormal blood vessel growth on the cornea. This condition, often seen in eye diseases, can disrupt corneal avascularity and lead to vision impairment.  It can be a major cause of blindness and significantly affect quality of life. Corneal neovascularization involves the formation of new blood vessels within the cornea, which can grow into normally avascular areas. This process is often triggered by injury or underlying eye diseases. While it can be treated with therapies like PDT (photodynamic therapy) and bevacizumab, corneal neovascularization remains a sight-threatening condition that requires careful management. \n\",14\n697,VEGFA GENE,,2\n791,AL NEOVASCULARIZATION,Area of study in corneal neovascularization,2\n695,VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-A),A protein involved in corneal angiogenesis,1\n700,INFECTIVE KERATITIS,Infective keratitis is a corneal pathological disease,1\n701,CHEMICAL BURN,Chemical burn is a corneal pathological disease,1\n702,CORNEAL LIMBAL STEM CELL DEFICIENCY,Corneal limbal stem cell deficiency is a corneal pathological disease,1\n703,MECHANICAL TRAUMA,Mechanical trauma is a corneal pathological disease,1\n704,IMMUNOLOGICAL REJECTION,Immunological rejection after keratoplasties is a complication of corneal pathological diseases,1\n2855,ZYP,\"The **ZYP** entity is a chemical compound that regulates the cell cycle.  It is also a company that utilizes its knowledge of miR-187 regulation to promote angiogenesis, and it produces Zishen Yutai pills. \n\",6\n301,PATIENTS,\"The **patients** encompass a diverse group of individuals.  They include those with subclinical AS, with 34 patients exhibiting this condition. Additionally, there are 360 patients diagnosed with â‰¥50% carotid stenosis. The patient population also includes those receiving treatment for cancer and undergoing ophthalmic examinations as part of various studies. Notably, some patients have been diagnosed with corneal neovascularization and treated with topical bevacizumab.  Furthermore, the group encompasses individuals who have received injections or medication, highlighting their involvement in medical interventions. Lastly, certain patients utilize ZYP for diverse health issues. \n\",9\n3340,UNIVERSITI,Universiti is a medical institution,1\n1247,BASELINE,Baseline measurement of vessel area,4\n1255,INVASION AREA,Area of the eye affected by tumor,2\n1256,VESSEL AREA,Area of the eye unaffected by tumor,2\n315,ZINC ION,Zinc ions are used to create nanoparticles,1\n1242,VEHICLE,\"The **vehicle** is a solution used as a placebo, and it also refers to a treatment option for patients. \n\",3\n1257,VEHICLE-TREATED PATIENTS,Patients who received bevacizumab treatment,1\n2735,IP,A study that measured the effects of a treatment on LDL-C levels,5\n2736,PLACEBO GROUP,\"The **PLACEBO GROUP** is a control group used in clinical trials.  It consists of participants who do not receive the active treatment being studied, instead receiving a placebo. This group is essential for comparison with the experimental group to determine if any observed effects are due to the treatment itself or other factors. The **PLACEBO GROUP** was specifically utilized in the study mentioned. \n\",5\n3391,TIME TO TREATMENT INITIATION,,1\n3392,BCVA OVER TIME,,1\n2729,MPH,\"The **MPH** (Medical Plaque Height) is a medical measurement that represents the maximum plaque height in the carotid arteries.  It is used to assess the severity of atherosclerosis, which is the buildup of plaque in the arteries. \n\",4\n2742,UMAB GROUP,Umab Group is a company that conducted the study,3\n2116,IPN,\"IPN is a measurement used to assess various aspects of cardiovascular health. It can be used as a measure of cholesterol levels, indicating both the level of cholesterol itself and the degree of cholesterol reduction achieved through treatment or lifestyle changes.  Additionally, IPN serves as an indicator of plaque buildup in the carotid arteries, providing insight into the risk of atherosclerosis. Notably, IPN is also linked to kidney disease, suggesting its potential role in monitoring overall health. In the context of cancer treatment, specifically for patients with high cholesterol, IPN can be used to assess the impact of evovolumab on these individuals. \n\",6\n2741,EVOLUCUMAB GROUP,The group that received evovolumab,2\n2737,LDL-C,,4\n1349,PREGNANCY,\"**Pregnancy** is a biological process where a woman's body undergoes significant physical and hormonal changes to support the growth and development of a fetus within the uterus. This period, often referred to as gestation, can be influenced by various factors, including the presence of certain medications or substances like **ZYP**.  The overall goal of pregnancy is to carry a developing baby safely in the womb until birth. \n\",1\n2856,ABORTION,ZYP may help prevent abortion,1\n2865,MIR-187,\"The **MIR-187** microRNA is a key player in gene regulation, influencing the expression of various genes. It plays a crucial role in regulating the cell cycle, impacting processes like DNA replication and cell division. \n\",1\n3390,EYE,\"The **eye** is a part of the body that can be affected by various conditions, including **PXE (Periodic-Exudative-Xeroderma)**.  It may also be treated with **VEGF (Vascular Endothelial Growth Factor) treatment**. The **eye** is specifically mentioned as being the location where VEGF treatment is applied. \n\",3\n5438,CHRONIC CORNEAL NEOVASCULARIZATION,A condition that causes abnormal blood vessel growth in the cornea,1\n5422,VERTEPORFIN,\"Verteporfin is a chemical used in Photodynamic Therapy (PDT) treatments. It is specifically employed to treat corneal neovascularization, a condition where new blood vessels form on the surface of the eye. \n\",1\n5439,60 MIN,Time interval after intravenous injection of verteporfin,1\n5440,150 J/CM<SUP>2</SUP>,Amount of light energy delivered during PDT,1\n2738,PERCENT REDUCTION OF LDL-C LEVEL,,1\n2739,LIPID-LOWERING TARGET,,1\n2740,LDL-C LEVELS,,1\n3389,ANTI-VEGF-INJECTIONS,Injections of anti-VEGF drugs,2\n792,THERAPEUTIC OUTCOMES,Potential outcomes of treatment for corneal neovascularization,2\n2744,EVOLOCUMAB GROUP,The group receiving evolocumab in the study,2\n2745,CAROTID IPN DECREASE,,2\n696,CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR)/CAS9,A gene editing tool,1\n1258,FIRST-PENETRATING KERATOPLASTY,First type of corneal transplant,2\n1259,WEEK 52,Time point in the study,1\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,combined_degree\n2391,PDT,BEVACIZUMAB,PDT combined with subconjunctival injection of bevacizumab was effective for the chronic corneal neovascularization,17\n242,CORNEAL NEOVASCULARIZATION,VEGFA GENE,The VEGFA gene plays a central role in corneal angiogenesis,16\n260,AL NEOVASCULARIZATION,CORNEAL NEOVASCULARIZATION,Al neovascularization area is a focus in the study of corneal neovascularization,16\n241,CORNEAL NEOVASCULARIZATION,VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF-A),CNV is a condition that affects VEGF-A expression,15\n244,CORNEAL NEOVASCULARIZATION,INFECTIVE KERATITIS,Corneal neovascularization can be caused by infective keratitis,15\n245,CORNEAL NEOVASCULARIZATION,CHEMICAL BURN,Corneal neovascularization can be caused by chemical burn,15\n246,CORNEAL NEOVASCULARIZATION,CORNEAL LIMBAL STEM CELL DEFICIENCY,Corneal neovascularization can be caused by corneal limbal stem cell deficiency,15\n247,CORNEAL NEOVASCULARIZATION,MECHANICAL TRAUMA,Corneal neovascularization can be caused by mechanical trauma,15\n248,CORNEAL NEOVASCULARIZATION,IMMUNOLOGICAL REJECTION,Corneal neovascularization can be caused by immunological rejection after keratoplasties,15\n1134,ZYP,PATIENTS,\"ZYP is used by patients for various health issues\nPatients who use ZYP for various health issues\",15\n1373,UNIVERSITI,CORNEAL NEOVASCULARIZATION,Universiti conducted a study on topical bevacizumab for corneal neovascularization,15\n390,PATIENTS,BASELINE,Baseline measurement of vessel area was taken for patients,13\n392,BEVACIZUMAB,INVASION AREA,\"Bevacizumab reduced invasion area by 75.8% compared to the control group\nInvasion area was reduced by 75.8% in the bevacizumab-treated group\",13\n393,BEVACIZUMAB,VESSEL AREA,\"Bevacizumab reduced vessel area by 75.8% compared to the control group\nVessel area was similar at 52 weeks postprocedure in cases of first and repeat corneal transplantation\",13\n110,BEVACIZUMAB,ZINC ION,Zinc ions are used to create nanoparticles,12\n388,VEHICLE,PATIENTS,Patients who received Vehicle,12\n396,BEVACIZUMAB,VEHICLE-TREATED PATIENTS,\"Vehicle-treated patients received bevacizumab treatment\nBevacizumab treatment for corneal transplantation in vehicle-treated patients\",12\n1082,IP,PLACEBO GROUP,IP was compared to placebo group for lipid lowering effect,10\n1377,PATIENTS,TIME TO TREATMENT INITIATION,Median observation period of 77 months (IQR 49; 126),10\n1378,PATIENTS,BCVA OVER TIME,Patients received a median number of 28.0 anti-VEGF injections,10\n1090,PLACEBO GROUP,MPH,The placebo group had a higher MPH than the evovolumab group,9\n1091,UMAB GROUP,IPN,Umab Group's treatment reduced IPN significantly,9\n1087,IPN,EVOLUCUMAB GROUP,\"The evovolumab group had a lower IPN than the placebo group\nIPN was measured in the evovolumab group\",8\n1894,BASELINE,LDL-C,Baseline LDL-C was used for comparison,8\n1895,LDL-C,MPH,MPH showed a significant difference from baseline in LDL-C patients,8\n1135,ZYP,PREGNANCY,ZYP may help with pregnancy,7\n1136,ZYP,ABORTION,ZYP may help prevent abortion,7\n1137,ZYP,MIR-187,ZYP regulates miR-187 expression to promote VEGF expression,7\n1383,EYE,TREATMENT,Treatment for PXE is initiated in one eye,7\n2394,CHRONIC CORNEAL NEOVASCULARIZATION,PDT,Chronic corneal neovascularization is treated with PDT,7\n2395,PDT,VERTEPORFIN,Verteporfin is a drug used in PDT treatment for corneal neovascularization,7\n2396,PDT,60 MIN,PDT is performed at 60 minutes after intravenous injection of verteporfin,7\n2397,PDT,150 J/CM<SUP>2</SUP>,PDT is performed with a fluence of 150 J/cm<sup>2</sup>,7\n1084,IP,PERCENT REDUCTION OF LDL-C LEVEL,IP showed a greater decrease in percent reduction of LDL-c level than placebo group,6\n1085,IP,LIPID-LOWERING TARGET,IP achieved a higher percentage of achieving lipid-lowering target compared to placebo group,6\n1086,IP,LDL-C LEVELS,IP showed a significant decrease in LDL-C levels compared to placebo group,6\n1089,EVOLUCUMAB GROUP,MPH,The evovolumab group had a higher MPH than the placebo group,6\n1379,ANTI-VEGF-INJECTIONS,EYE,Anti-VEGF injections were given to the eye,5\n261,AL NEOVASCULARIZATION,THERAPEUTIC OUTCOMES,The study of al neovascularization area is a focus in the discussion of therapeutic outcomes for corneal neovascularization,4\n1095,EVOLOCUMAB GROUP,CAROTID IPN DECREASE,The evolocumab group had a significantly greater reduction in carotid IPN than the placebo group,4\n243,CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS (CRISPR)/CAS9,VEGFA GENE,CRISPR/Cas9 can edit the VEGFA gene to suppress its expression,3\n398,FIRST-PENETRATING KERATOPLASTY,WEEK 52,First penetrating keratoplasty was performed at week 52,3\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "role": "user"}], "parameters": {"model": "gemma2:2b", "frequency_penalty": 0.0, "max_tokens": 2000, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0, "response_format": {"type": "json_object"}}}, "key": "chat_create_community_report_b10d3322e0e8e509233e93b03dd435aed051e72ce0e9042cb6bc38005e862766_v2"}